Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients With Relapsing Remitting Multiple Sclerosis - RED4MS Trial

NCT06430671 is registered in ClinicalTrials.gov with Cellerys AG as lead sponsor.

NCT NCT06430671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06430671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients With Relapsing Remitting Multiple Sclerosis - RED4MS Trial
Lead sponsor
Cellerys AG
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2024
Completion date
December 23, 2025
Enrollment
11 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis (rrms)